<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TUBOCURARINE CHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(too-boe-kyoo-ar'een)<br/><span class="topboxtradename">Tubocurarine Chloride<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">nondepolarizing skeletal muscle relaxant</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>3 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Curare alkaloid that is a nondepolarizing neuromuscular blocking agent extracted from the plant <i>Chondodendron tomentosum</i>. Produces skeletal muscle relaxation or paralysis by competing with acetylcholine at cholinergic receptor sites on skeletal
         muscle endplate and thus blocks nerve impulse transmission. Also has histamine-releasing and ganglionic blocking properties.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blocks nerve impulse transmission to skeletal muscles, thus producing relaxation or paralysis of skeletal muscles. Utilized
         with general anesthesia and as an adjunct to mechanical ventilation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To induce skeletal muscle relaxation as adjunct to general anesthesia, to facilitate management of mechanical ventilation,
         to reduce intensity of muscle contractions in tetanus and in pharmacologically or electrically induced convulsions, to treat
         spastic states in children, and for diagnosis of myasthenia gravis when conventional tests have been inconclusive.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to curare preparations; when histamine release is a hazard; hyperthermia; electrolyte imbalance; acidosis;
         neuromuscular disease; kidney disease. Safety during pregnancy (category C) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired cardiovascular, kidney, liver, pulmonary, or endocrine function; hypotension; carcinomatosis; thyroid disorders;
         collagen diseases; porphyria; familial periodic paralysis; history of allergies; myasthenia gravis; older adults or debilitated
         patients.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adjunct to General Anesthesia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 69 mg followed by 34.5 mg in 35 min if necessary<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.20.5 mg/kg followed by 0.040.1 mg/kg prn to maintain paralysis<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span>
<i> 0.3 mg/kg followed by 0.1 mg/kg prn to maintain paralysis<br/><br/><span class="indicationtitle">Electroshock</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.165 mg/kg administered slowly IV<br/><br/><span class="indicationtitle">Diagnosis of Myasthenia Gravis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.0040.033 mg/kg<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: Verify correct IV dilution and rate of IV injection for neonates, infants, children with physician.
         		
      </p>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span>  May be given undiluted (3 mg/mL).  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give bolus dose over 6090 sec.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<span class="classification">barbiturates</span>, <b>sodium bicarbonate;</b>
<b>trimethaphan.</b>
</p>
<ul>
<li>Do not use solutions of drug if more than faintly discolored.</li>
<li>Do not mix in same syringe with solutions that have a high pH such as barbiturates and sodium bicarbonate.</li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Slight dizziness, feeling of warmth, <span class="speceff-life">malignant hyperthermia</span>, hypersensitivity reactions. <span class="typehead">Musculoskeletal:</span> Profound and prolonged muscle weakness and flaccidity. <span class="typehead">Respiratory:</span>
<span class="speceff-life">Respiratory depression</span>, hypoxia, <span class="speceff-life">apnea</span>, increased bronchial and salivary secretions, bronchospasm. <span class="typehead">GI:</span> Decreased GI motility. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension,</span>
<span class="speceff-life">circulatory collapse</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">skeletal muscle relaxants</span>, <span class="classification">inhaled anesthetics</span>, <span class="classification">aminoglycosides</span>, <b>polymyxin B,</b>
<b>clindamycin,</b>
<b>quinidine,</b>
<b>quinine,</b>
<b>procainamide,</b>
<span class="classification">diuretics</span>, <b>amphotericin B</b> may potentiate neuromuscular blockade. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span>  25 min. <span class="typehead">Duration:</span> 2030 min if used alone. <span class="typehead">Metabolism:</span> Demethylated in liver. <span class="typehead">Elimination:</span> 3375% excreted in urine within 24 h; 11% excreted in bile; crosses placenta. <span class="typehead">Half-Life:</span> 13 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain baseline kidney function and determinations of serum electrolytes. Electrolyte imbalance (particularly potassium
            and magnesium) can potentiate the effects of nondepolarizing neuromuscular blocking agents.
         </li>
<li>Monitor BP, vital signs, and airway until assured of patient's recovery from drug effects. Ganglionic blockade (hypotension)
            and histamine liberation (increased salivation, bronchospasm) and neuromuscular blockade (respiratory depression) are known
            effects of tubocurarine.
         </li>
<li>Be aware that selective muscle paralysis following drug administration occurs in the following sequence: jaw muscles, levator
            eyelid muscles and other muscles of head and neck, limbs, intercostals and diaphragm, abdomen, trunk. Facial and diaphragm
            muscles are first to recover, followed in order by legs, arms, shoulder girdle, trunk, larynx, hands, feet, pharynx. Muscle
            function is usually restored within 90 min.
         </li>
<li>Measure and record I&amp;O ratio during day of drug administration. Renal dysfunction will prolong drug action. Peristaltic action
            may be suppressed. Check for bowel sounds.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Tubocurarine is retained in the body long after effects of neuromuscular blockade appear to have dissipated. Report residual
            muscle weakness to physician.
            						
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>